Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Japanese pharmaceutical company Daiichi Sankyo is set to develop a mRNA vaccine candidate to protect against Covid-19 infection in the country.
Currently, the company is part of Covid-19 vaccine research and development (R&D) being led by the University of Tokyo. The project, Fundamental Research on the Control of a Novel Coronavirus (2019-nCoV), is supported by the Japan Agency for Medical Research and Development (AMED).
In addition, the company is part of a basic, genetic (mRNA) vaccine research project, titled Development of a Genetic Vaccine for 2019-nCoV.